Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, today announced the signing of a multi-target discovery collaboration and license agreement with Merck, known as MSD outside the United States and Canada. The agreement combines Protillion's proprietary platform with Merck's global expertise in the discovery of novel therapeutic candidates.